Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jul 15;38(27):3095–3106. doi: 10.1200/JCO.19.02103

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 by American Society of Clinical Oncology

PMC Copyright notice

FIG A2. — Key variates and efficacy outcomes of axicabtagene ciloleucel. (A) Overall response rate (ORR) stratified by multiple covariates. (B) Duration of response curves stratified by ZUMA-1 eligibility and use of bridging therapy. (C) Progression-free survival (PFS) stratified by ZUMA-1 eligibility and use of bridging therapy. (D) Overall survival (OS) stratified by ZUMA-1 eligibility and use of bridging therapy. CLL, chronic lymphocytic leukemia; CRS, cytokine release syndrome; DLBCL, diffuse large B cell lymphoma; ECOG, Eastern Cooperative Oncology Group; FL, follicular lymphoma; GCB, germinal center B cell; HGBL, high-grade B-cell lymphoma; MZL, marginal zone lymphoma; NR, not reached; NT, neurotoxicity; PMBCL, primary mediastinal large B-cell lymphoma; ZE, ZUMA-1 eligible; ZI, ZUMA-1 ineligible for reasons other than bridging therapy; ZI-BR, ZUMA-1 ineligible solely because of the use of bridging therapy.